Feasibility and Safety of Targeting Neutral vs Liberal Fluid Balance in Traumatic Brain Injured Patients- LIMIT-TBI Trial

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasme University Hospital

About this trial

The LIMIT-TBI trial is a multicenter, international, randomized, phase II clinical trial designed to evaluate the feasibility and safety of targeting a neutral fluid balance compared to standard care in critically ill adult patients with traumatic brain injury (TBI).

Fluid therapy is a cornerstone of TBI management, but optimal fluid balance remains uncertain, with both fluid overload and restriction potentially leading to adverse outcomes. This study aims to determine whether maintaining a daily fluid balance close to zero (±500 mL) during the first 5 days of ICU admission is achievable and safe.

Participants will be randomized within 48 hours of ICU admission to either a protocolized neutral fluid balance strategy or standard care. Outcomes include feasibility of achieving the target balance, organ complications, hemodynamic parameters, ICU resource utilization, and mortality and neurological outcomes up to 6 months.

Eligibility criteria

Qualifiers

Adult patients with traumatic brain injury (isolated or associated with extracranial injuries), with or without intracranial pressure monitoring

Admission to the intensive care unit

Age >18 years

Enrollment within 48 hours after ICU admission

Disqualifiers

Enrollment in another clinical trial not approved for co-enrollment

Pregnancy or suspected pregnancy

Concomitant hemorrhagic shock expected to require surgical treatment within 24 hours from inclusion or requiring massive transfusion protocol

Hemodynamic instability at ICU admission, defined as heart rate >120 beats/min and systolic arterial pressure <100 mmHg despite at least 1 L of fluid resuscitation, or requirement for high-dose norepinephrine (>0.5 mcg/kg/min) or any inotropic support

Trial design

Treatments tested in this trial

  • Neutral Fluid Balance Strategy

Treatment groups

88 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Erasme University Hospital

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator

Azienda Ospedaliero, Universitaria Pisana

Collaborator

Hospital Clínico Universitario de Valencia

Collaborator

All India Institute of Medical Sciences

Collaborator

Erasmus University Rotterdam

Collaborator

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Collaborator